• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Innovation and Global Clinical Trial Participation Are the Focus of CenterWatch’s Latest Special Report on China’s Drug Development Industry

Innovation and Global Clinical Trial Participation Are the Focus of CenterWatch’s Latest Special Report on China’s Drug Development Industry

October 2, 2009
CenterWatch Staff

BOSTON—China’s new investments in its domestic pharma industry are beginning to drive growth and reforms that are stimulating a new drug development culture, according to CenterWatch’s latest special report, China: A New Era of Innovation in Drug Development.

 Scheduled for release in early October, the fifth report in CenterWatch’s clinical research series reveals the initial benefits of China’s efforts and the various reforms in progress, as well as a look at the further initiatives needed to make the country a major player in the drug development arena.

 “CenterWatch has analyzed how China’s regulatory reforms can spur innovation in the domestic drug development community, as well as benefit Big Pharma that want to include China in their global drug development programs,” says Sara Gambrill, senior editor at CenterWatch and author of the report. In addition, the report discusses Big Pharma’s long-range plans to invest in the research and development sector and the talent needed in the area to successfully run trials at a global level.

Other key takeaways include a list of select CROs in the region, an up-to-date pipeline of drugs currently in development, and several charts and figures that make this an important informational resource for sponsors and CROs seeking to expand their programs in the region.

For more information or to purchase China: A New Era of Innovation in Drug Development, visit the CenterWatch bookstore at http://store.centerwatch.com.

Upcoming Events

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing